Peer-Reviewed Publications

CPCE investigators are international experts in their clinical effectiveness-related fields, and have authored hundreds of pediatric research articles in leading peer-reviewed journals. From here you can access CPCE journal article abstracts by author, title, or year.

Found 45 results
Author [ Title(Asc)] Year
Filters: Author is Alonzo, Todd A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Getz KD, Alonzo TA, Sung L, et al. "Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2021:e29313.
Vujkovic M, Attiyeh EF, Ries RE, et al. "Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group." Cancer Genet. 2015;208(7-8):408-13.
Smith JL, Ries RE, Hylkema T, et al. "Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study." Clin. Cancer Res.. 2019.
Getz KD, Li Y, Alonzo TA, et al. "Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2015;62(10):1775-81.
Miller TP, Getz KD, Kavcic M, et al. "A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group." Leuk. Lymphoma. 2016:1-8.
Miller TP, Troxel AB, Li Y, et al. "Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2015;62(7):1184-9.
Vujkovic M, Aplenc R, Alonzo TA, Gamis AS, Li Y. "Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group." Front Genet. 2016;7:139.
Hoff FW, van Dijk AD, Qiu Y, et al. "Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study." Haematologica. 2022.
Johnston DL, Alonzo TA, Gerbing RB, et al. "Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2017.
Miller TP, Li Y, Kavcic M, et al. "Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: A report from the Children's Oncology Group." Haematologica. 2017.
Lamba JK, Chauhan L, Shin M, et al. "CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531." J. Clin. Oncol.. 2017:JCO2016712513.
Pollard JA, Loken MR, Gerbing RB, et al. "CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531." J. Clin. Oncol.. 2016;34(7):747-55.
Lamble AJ, Brodersen LEidenschin, Alonzo TA, et al. "CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group." J Clin Oncol. 2021:JCO2101595.

Pages